230 related articles for article (PubMed ID: 15018248)
21. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
22. Effects of drospirenone/estrogen combinations on bone metabolism.
Christiansen C
Climacteric; 2005 Oct; 8 Suppl 3():35-41. PubMed ID: 16203654
[TBL] [Abstract][Full Text] [Related]
23. Clinical experiences with drospirenone: from reproductive to postmenopausal years.
Pérez-López FR
Maturitas; 2008 Jun; 60(2):78-91. PubMed ID: 18468818
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
[TBL] [Abstract][Full Text] [Related]
25. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
[TBL] [Abstract][Full Text] [Related]
26. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.
Muhn P; Fuhrmann U; Fritzemeier KH; Krattenmacher R; Schillinger E
Ann N Y Acad Sci; 1995 Jun; 761():311-35. PubMed ID: 7625729
[TBL] [Abstract][Full Text] [Related]
27. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
Genazzani AR; Schmelter T; Schaefers M; Gerlinger C; Gude K
Climacteric; 2013 Aug; 16(4):490-8. PubMed ID: 23531117
[TBL] [Abstract][Full Text] [Related]
28. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril.
Preston RA; Alonso A; Panzitta D; Zhang P; Karara AH
Am J Hypertens; 2002 Sep; 15(9):816-22. PubMed ID: 12219878
[TBL] [Abstract][Full Text] [Related]
29. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
[TBL] [Abstract][Full Text] [Related]
30. Evolution of progestins. Focus on the novel progestin drospirenone.
Thorneycroft IH
J Reprod Med; 2002 Nov; 47(11 Suppl):975-80. PubMed ID: 12497671
[TBL] [Abstract][Full Text] [Related]
31. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.
Fuhrmann U; Krattenmacher R; Slater EP; Fritzemeier KH
Contraception; 1996 Oct; 54(4):243-51. PubMed ID: 8922878
[TBL] [Abstract][Full Text] [Related]
32. Menopause and cardiovascular disease: the evidence.
Rosano GM; Vitale C; Marazzi G; Volterrani M
Climacteric; 2007 Feb; 10 Suppl 1():19-24. PubMed ID: 17364594
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment.
von Schoultz B
Climacteric; 2003 Aug; 6 Suppl 2():24-32. PubMed ID: 14669841
[TBL] [Abstract][Full Text] [Related]
34. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
[TBL] [Abstract][Full Text] [Related]
35. Progestin may modify the effect of low-dose hormone therapy on mammographic breast density.
Panoulis C; Lambrinoudaki I; Vourtsi A; Augoulea A; Kaparos G; Aravantinos L; Christodoulakos G; Creatsas G
Climacteric; 2009 Jun; 12(3):240-7. PubMed ID: 19387881
[TBL] [Abstract][Full Text] [Related]
36. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
Oelkers W
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403
[TBL] [Abstract][Full Text] [Related]
37. Effects of drospirenone on cardiovascular markers in human aortic endothelial cells.
Seeger H; Wallwiener D; Mueck AO
Climacteric; 2009 Feb; 12(1):80-7. PubMed ID: 18979300
[TBL] [Abstract][Full Text] [Related]
38. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension.
White WB; Hanes V; Chauhan V; Pitt B
Hypertension; 2006 Aug; 48(2):246-53. PubMed ID: 16801478
[TBL] [Abstract][Full Text] [Related]
39. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
Boschitsch E; Skarabis H; Wuttke W; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
[TBL] [Abstract][Full Text] [Related]
40. Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms.
Ylikorkala O
Climacteric; 2005 Oct; 8 Suppl 3():1-3. PubMed ID: 16203649
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
